Latest / AI Investment Edge: Stocks, Markets & Money / EP 43 | TransMedics Stock Analysis: Will Flying Organs Send It Soaring?
Transcript
- 0:00SPEAKER_00: Imagine for a second that you invent like a genuinely revolutionary medical device,
- 0:05SPEAKER_00: something that can literally keep a human heart beating or, you know,
- 0:09SPEAKER_00: lungs breathing outside the human body.
- 0:11SPEAKER_00: The technology is brilliant.
- 0:12SPEAKER_00: The hospitals want it and the margins look beautiful.
- 0:15SPEAKER_01: Oh, yeah. Total game changer.
- 0:17SPEAKER_00: But then to actually scale the business,
- 0:19SPEAKER_00: you realize you can't just rely on commercial FedEx or I don't know,
- 0:23SPEAKER_00: standard hospital transport.
- 0:25SPEAKER_00: You actually have to go out and build your own specialized flight network.
- 0:29SPEAKER_01: Which is a massive leap.
- 0:30SPEAKER_00: Exactly.
- 0:32SPEAKER_00: You have to buy planes.
- 0:33SPEAKER_00: You have to coordinate flight crews.
- 0:35SPEAKER_00: It is like it's like Apple inventing the iPhone,
- 0:39SPEAKER_00: but then deciding they also need to build their own cell towers
- 0:42SPEAKER_00: and lay their own underwater fiber optic cables just to sell the phones.
- 0:46SPEAKER_01: Yeah, that is a great way to put it.
- 0:48SPEAKER_00: The device is genius, but that physical infrastructure spend, that is terrifying.
- 0:52SPEAKER_01: It completely rewrites the financial DNA of the entire company.
- 0:56SPEAKER_01: You know, you are no longer just balancing medical innovation and clinical trials.
- 1:00SPEAKER_01: You are suddenly like managing aviation logistics, fuel costs and pilot schedules.
- 1:05SPEAKER_00: Exactly. And that is the massive core tension of today's deep dive.
- 1:09SPEAKER_00: We are looking at Transmedics,
- 1:10SPEAKER_00: which is this organ preservation innovator that has decided
- 1:13SPEAKER_00: to coordinate its own specialist teams and aircraft.
- 1:17SPEAKER_00: So for you listening, we have to ask the big question today.
- 1:20SPEAKER_00: Is this aviation network a massive competitive advantage
- 1:24SPEAKER_00: that will compound your shareholder wealth?
- 1:26SPEAKER_00: Or is it just a brutally expensive physical machine that is going
- 1:30SPEAKER_00: to eat up all those beautiful medical device margins?
- 1:33SPEAKER_01: It is arguably one of the most fascinating debates in the market right now.
- 1:37SPEAKER_00: Definitely.
- 1:38SPEAKER_00: And to explore it, we are using source material from AI Investment Edge from iPulse AI.
- 1:44SPEAKER_00: That research was dated November 10th, 2026.
- 1:46SPEAKER_01: Yeah. And if we look at their public expert weighted ratings from that report,
- 1:51SPEAKER_01: they currently have transmedics at a neutral rating for the shorter horizon,
- 1:55SPEAKER_01: but a strong buy at the longer horizon.
- 1:57SPEAKER_00: And the immediate action recommendation is no action.
- 2:01SPEAKER_00: Keep monitoring.
- 2:02SPEAKER_00: Just as a reminder for you, this is a research assessment,
- 2:04SPEAKER_00: not a personalized order for your portfolio.
- 2:06SPEAKER_01: Always good to remember.
- 2:08SPEAKER_00: Okay, let's unpack this because that split rating is incredibly telling to me.
- 2:12SPEAKER_00: The new term model target leaves like very little room above the dated market reference.
- 2:17SPEAKER_00: But that longer path, it requires years of flawless execution
- 2:22SPEAKER_00: to actually hit those upside targets. Precisely.
- 2:25SPEAKER_01: I mean, to truly understand why those targets are so divergent,
- 2:28SPEAKER_01: we first have to understand what transmedics actually does on a clinical level.
- 2:32SPEAKER_00: Right.
- 2:33SPEAKER_01: They are a NASDAQ-listed company that produces what they call the Organ Care System, or OCS.
- 2:39SPEAKER_01: It is currently used for hearts, lungs, and livers.
- 2:41SPEAKER_00: Okay.
- 2:42SPEAKER_01: And the fundamental differentiator here is that they utilize warm perfusion rather
- 2:47SPEAKER_01: than relying solely on traditional static cold storage.
- 2:51SPEAKER_00: Right. And I actually want to pause and clarify a really common misconception here.
- 2:55SPEAKER_00: When the medical field says static cold storage, they mean they are chilling the organs.
- 3:00SPEAKER_01: Yes, exactly.
- 3:01SPEAKER_00: They are not literally freezing them solid like a bag of peas.
- 3:04SPEAKER_01: No, definitely not.
- 3:05SPEAKER_00: And while the Transmedics OCS maintains a functioning, warm,
- 3:09SPEAKER_00: oxygenated environment during transport, which is an incredible medical feat,
- 3:13SPEAKER_00: that organ still remains entirely time critical.
- 3:17SPEAKER_01: That is a crucial point. Yeah.
- 3:19SPEAKER_00: Viability is still limited throughout transport.
- 3:21SPEAKER_00: The OCS is not giving the organ an unlimited shelf life and, you know,
- 3:25SPEAKER_00: it does not stop the ticking clock.
- 3:27SPEAKER_01: Right. There's no magic pause button.
- 3:29SPEAKER_00: Exactly.
- 3:30SPEAKER_00: You are maintaining a functioning environment during a time-critical journey,
- 3:34SPEAKER_00: not just dropping a parcel in a fridge.
- 3:37SPEAKER_00: And because it requires such highly specific, active handling,
- 3:41SPEAKER_00: Transmedics earns service revenue from its national OCS program.
- 3:45SPEAKER_00: They handle the procurement, the perfusion management, and the actual physical transport.
- 3:50SPEAKER_00: It naturally reminds me of our previous deep dive on RxSight in episode 40.
- 3:54SPEAKER_00: We looked at how a genuinely useful piece of medical technology translates
- 3:58SPEAKER_00: into repeat structural demand.
- 4:00SPEAKER_01: Right. Very similar dynamic.
- 4:02SPEAKER_00: Transmedic sells disposable sets for every single organ transported.
- 4:06SPEAKER_00: So there is that recurring revenue model.
- 4:09SPEAKER_00: But as we've learned, just because a medical technology is incredibly useful
- 4:12SPEAKER_00: to humanity, that alone does not guarantee attractive shareholder returns.
- 4:16SPEAKER_01: Which is the perfect bridge into our financial findings,
- 4:18SPEAKER_01: starting with their earnings and cash quality.
- 4:20SPEAKER_01: Let's look at their third quarter results, which were released on November 5th.
- 4:23SPEAKER_00: Okay, lay the numbers on us.
- 4:25SPEAKER_01: Their revenue was roughly $203 million.
- 4:28SPEAKER_01: That is up 41% year over year.
- 4:31SPEAKER_01: And their company-defined organic growth was 35%.
- 4:34SPEAKER_00: Sure. I mean, 35% organic growth sounds absolutely amazing on a slide deck,
- 4:38SPEAKER_00: but if they are buying airplanes and hiring flight crews to achieve it,
- 4:42SPEAKER_00: how much of that growth is actually trickling down to the bottom line?
- 4:44SPEAKER_01: That is exactly the right question to ask, because the profit picture is, well,
- 4:48SPEAKER_01: it's complicated.
- 4:49SPEAKER_01: Operating profit actually rose to about $28 million.
- 4:52SPEAKER_00: Okay, that's good.
- 4:53SPEAKER_01: But net profit fell to about $17 million, down from roughly $24 million a year earlier.
- 4:58SPEAKER_00: How does their operating profit go up but their net profit goes down so significantly?
- 5:02SPEAKER_00: Like what is driving that math?
- 5:05SPEAKER_01: It comes down to taxes and financing mostly.
- 5:07SPEAKER_01: A tax expense of about $7 million replaced a prior year tax benefit of about $1 million.
- 5:12SPEAKER_00: Oh wow, okay.
- 5:13SPEAKER_01: So right there you have an $8 million swing.
- 5:17SPEAKER_01: Add in rising financing costs from all this expansion and your net profit just takes
- 5:21SPEAKER_01: a direct hit. Makes sense.
- 5:22SPEAKER_01: But it is important for investors to realize that a falling net profit
- 5:26SPEAKER_01: in this specific case does not mean the core operating profit fell.
- 5:31SPEAKER_01: However, the cash tells a slightly different story.
- 5:35SPEAKER_00: How so?
- 5:36SPEAKER_01: If we look at the first nine months, operating cash flow was about $78 million.
- 5:41SPEAKER_01: That is down from roughly $158 million a year earlier.
- 5:45SPEAKER_00: Because all their cash is getting tied up, right?
- 5:47SPEAKER_00: I mean, when you are building a physical logistics network,
- 5:51SPEAKER_00: you have to buy the parts, hold the inventory,
- 5:53SPEAKER_00: and pay your own teams well before the hospitals actually pay your invoices.
- 5:57SPEAKER_01: Exactly.
- 5:58SPEAKER_00: Which means we need to look at their profit margins.
- 6:01SPEAKER_00: Because if revenue was up 41%, you'd normally expect margins to expand. Right.
- 6:06SPEAKER_00: But this logistics network is heavy.
- 6:09SPEAKER_01: Very heavy.
- 6:10SPEAKER_01: In the third quarter, their gross margins stayed pretty steady, right around 59%.
- 6:14SPEAKER_01: But the operating margin dropped to about 14%, which is down from about, you know, 16%.
- 6:21SPEAKER_00: Why are we seeing that compression?
- 6:23SPEAKER_00: Is it just the planes?
- 6:24SPEAKER_01: It is the broader service mix.
- 6:26SPEAKER_01: The lower margin services, specifically the logistics and the transport,
- 6:30SPEAKER_01: are growing much faster than the high margin medical device sales.
- 6:33SPEAKER_00: Ah, right.
- 6:35SPEAKER_01: At the same time, their research, clinical programs, staffing,
- 6:38SPEAKER_01: and physical infrastructure simply cost more to maintain.
- 6:42SPEAKER_00: Yeah, that makes sense.
- 6:43SPEAKER_01: Yes, having more transplant cases can eventually spread your fixed costs out,
- 6:47SPEAKER_01: but a heavier transport mix in your overall revenue will continually restrain
- 6:51SPEAKER_01: that blended margin.
- 6:52SPEAKER_00: We talked about this exact dynamic when we analyzed Medtronic in episode 27.
- 6:56SPEAKER_00: You always have to separate the durable medical demand
- 6:59SPEAKER_00: from the actual financial returns left for the shareholders at the end of the day.
- 7:03SPEAKER_00: A rapidly growing business isn't automatically a more profitable one.
- 7:07SPEAKER_01: Which brings us to the health of their balance sheet.
- 7:10SPEAKER_01: If you are going to be an infrastructure heavy business, you need capital.
- 7:13SPEAKER_01: At the end of September, their cash position was about $493 million plus
- 7:19SPEAKER_01: about $18 million of separate restricted cash.
- 7:23SPEAKER_00: And it is really important to note that the $18 million in restricted cash is
- 7:26SPEAKER_00: in addition to that main $493 million figure.
- 7:31SPEAKER_00: But, you know, if you're an investor looking at their balance sheet,
- 7:33SPEAKER_00: you also see some massive liabilities that might make your heart skip a beat.
- 7:37SPEAKER_01: They do have substantial obligations.
- 7:39SPEAKER_01: They have $460 million in convertible notes due June 1st, 2028, a bank loan,
- 7:45SPEAKER_01: and a massive finance lease for their headquarters in Somerville.
- 7:49SPEAKER_00: Let's break down those convertible notes first, just to be clear for everyone.
- 7:52SPEAKER_00: Convertible notes are essentially debt that can turn into equity down the line.
- 7:57SPEAKER_01: Yes, exactly.
- 7:58SPEAKER_00: So if you are a shareholder, you have to keep an eye on that,
- 8:01SPEAKER_00: because if those notes convert into stock,
- 8:03SPEAKER_00: your slice of the ownership pie gets diluted.
- 8:06SPEAKER_00: But I also want to clarify that Somerville headquarters lease
- 8:09SPEAKER_00: because it looks incredibly intimidating on paper.
- 8:12SPEAKER_01: It does. Yeah.
- 8:14SPEAKER_01: The lease liability is roughly $352 million.
- 8:18SPEAKER_01: And the accounting actually assumes the exercise of a purchase option,
- 8:21SPEAKER_01: which totals about $375 million through the end of 2027.
- 8:26SPEAKER_00: But let's explain what that means in reality.
- 8:29SPEAKER_00: This is strictly an assumed property purchase built into the accounting schedule.
- 8:33SPEAKER_00: It is essentially the accountants mapping out the most likely future scenario.
- 8:38SPEAKER_00: It is not cash they have already spent,
- 8:40SPEAKER_00: and it is absolutely not an unconditional bill for new aircraft.
- 8:44SPEAKER_00: It is just the accounting mechanics for their headquarters building.
- 8:47SPEAKER_01: That distinction is vital.
- 8:49SPEAKER_01: Just because they have cash doesn't mean they are debt-free,
- 8:52SPEAKER_01: but you also can't treat long-term accounting liabilities as cash
- 8:56SPEAKER_01: that has already walked out the door today.
- 8:58SPEAKER_00: Right.
- 8:58SPEAKER_01: Which requires us to look at a very specific cash bridge to see what they are actually spending.
- 9:06SPEAKER_01: Let's walk through this carefully.
- 9:08SPEAKER_01: Over the nine months, they generated roughly $78 million in operating cash.
- 9:13SPEAKER_00: Okay.
- 9:15SPEAKER_01: You subtract about $52 million of actual cash equipment purchases.
- 9:20SPEAKER_00: So that leaves about $26 million before we even factor in acquisitions, financing,
- 9:24SPEAKER_00: and currency movements?
- 9:26SPEAKER_01: Correct.
- 9:27SPEAKER_01: And then regarding their aviation acquisition, PAD,
- 9:30SPEAKER_01: about $5 million of separate cash went into that investment,
- 9:34SPEAKER_01: net of the cash acquired.
- 9:35SPEAKER_00: Okay, got it.
- 9:37SPEAKER_01: Now, a lot of investors look at their research expense, which was about $86 million,
- 9:42SPEAKER_01: and ask if we should deduct that too.
- 9:44SPEAKER_00: Yeah, that seems like a massive cash drain.
- 9:46SPEAKER_00: Do we subtract that $86 million from the remaining $26 million?
- 9:50SPEAKER_01: No, and this is a crucial insight for anyone analyzing these statements.
- 9:54SPEAKER_01: That research expense is an operating expense.
- 9:58SPEAKER_01: It is already reflected inside that initial $78 million operating cash flow figure.
- 10:03SPEAKER_00: Oh, okay.
- 10:03SPEAKER_01: You never subtract it twice. And furthermore,
- 10:06SPEAKER_01: saying it is reflected does not necessarily mean every single dollar
- 10:10SPEAKER_01: of that $86 million accounting expense was actually paid in hard cash
- 10:14SPEAKER_01: during this specific period.
- 10:16SPEAKER_00: It's remarkably similar to the core lesson regarding Boeing in Episode 38.
- 10:21SPEAKER_00: Physical capacity, whether it's building new planes or developing new headquarters,
- 10:25SPEAKER_00: and the actual free cash delivered to shareholders are very, very different things.
- 10:29SPEAKER_01: Exactly.
- 10:30SPEAKER_01: So how does all this complex accounting translate to their actual valuation?
- 10:34SPEAKER_00: Right. Let's talk numbers.
- 10:36SPEAKER_01: Setting up the base, bull, and bear scenarios.
- 10:38SPEAKER_01: We are using the dated November 9th daily close, which was roughly $94 a share.
- 10:44SPEAKER_01: We are not using a live to the minute quote here.
- 10:46SPEAKER_00: Okay.
- 10:46SPEAKER_00: So based on that $94 reference point, what are the AI models actually targeting?
- 10:52SPEAKER_01: The fixed score cast dates are the third quarter of 2027 and the third quarter of 2031.
- 10:58SPEAKER_00: Okay.
- 10:58SPEAKER_01: The nearer target is about $97. Okay.
- 11:02SPEAKER_01: That implies roughly a 3% cumulative price gain.
- 11:05SPEAKER_01: But the longer term 2031 target is about $183,
- 11:10SPEAKER_01: which implies roughly a 95% cumulative gain.
- 11:13SPEAKER_00: Wow, that's a big jump.
- 11:14SPEAKER_01: Yeah.
- 11:15SPEAKER_01: And it's important to note that no dividends are assumed in any of these targets.
- 11:19SPEAKER_00: And just to reiterate, those are cumulative gains to those fixed dates, not annualized returns.
- 11:24SPEAKER_00: But what actually needs to happen in the real world for them
- 11:26SPEAKER_00: to hit those wildly different scenarios?
- 11:28SPEAKER_01: Well, in the base scenario, you need to see more Oregon cases,
- 11:32SPEAKER_01: steady recurring sales, and margins gradually catching up
- 11:35SPEAKER_01: to the heavy infrastructure spend.
- 11:37SPEAKER_00: Okay, that sounds reasonable.
- 11:38SPEAKER_01: What about the bull case?
- 11:40SPEAKER_01: The bull scenario demands strong clinical expansion,
- 11:43SPEAKER_01: new indications for the technology, and highly efficient,
- 11:46SPEAKER_01: economically dense European flight routes.
- 11:49SPEAKER_00: And the bear scenario?
- 11:50SPEAKER_01: The bare scenario is triggered by pricing pressure from hospitals, clinical delays,
- 11:55SPEAKER_01: or a situation where the aircraft and facilities remain way too costly relative
- 11:58SPEAKER_01: to the actual volume of Oregon flights.
- 12:01SPEAKER_00: To give you listening a visceral sense of the range here,
- 12:04SPEAKER_00: let's look at one high-weight primary source grounded advisor.
- 12:09SPEAKER_00: And just to be completely clear, this is a single advisor scenario, not a weighted consensus.
- 12:14SPEAKER_01: Right.
- 12:15SPEAKER_00: Their base target for September 2031 is roughly $143,
- 12:19SPEAKER_00: and that assumes no material commercialization revenue from kidneys.
- 12:23SPEAKER_00: Their bull case is roughly $255, but their bear case is It
- 12:31SPEAKER_01: is a massive spread.
- 12:32SPEAKER_00: I mean, a $40 bear case versus a $255 bull case, that isn't just a difference of opinion.
- 12:39SPEAKER_00: That is two completely different realities.
- 12:42SPEAKER_00: What drives that kind of volatility in the projections?
- 12:44SPEAKER_01: The valuation is incredibly sensitive to margin compression.
- 12:48SPEAKER_01: It is sensitive to the potential dilution from those convertibles we discussed.
- 12:53SPEAKER_01: And most importantly, it depends
- 12:54SPEAKER_01: on how efficiently they can utilize this physical network over thousands of flights.
- 12:59SPEAKER_00: So if we break this down logically into drivers and frictions,
- 13:03SPEAKER_00: the core drivers pushing the stock up are obvious.
- 13:05SPEAKER_00: Increased transplant adoption by surgeons
- 13:08SPEAKER_00: and this incredibly integrated reliable logistics network.
- 13:11SPEAKER_01: Yeah, definitely.
- 13:12SPEAKER_00: But the frictions dragging it down are the dilution of their overall profit margins
- 13:17SPEAKER_00: by the service mix, high aircraft maintenance costs
- 13:20SPEAKER_00: and intense reimbursement scrutiny from hospital budgets.
- 13:24SPEAKER_01: And we also have to consider the absolute extremes, you know, the tails.
- 13:27SPEAKER_00: Right.
- 13:28SPEAKER_01: The upside tail is a genuinely successful OCS kidney development.
- 13:31SPEAKER_01: If that works, it creates an entirely new franchise that just plugs right
- 13:35SPEAKER_01: into their existing flight network, drastically increasing their volume.
- 13:38SPEAKER_00: And the downside?
- 13:39SPEAKER_01: The downside tail would be a major clinical failure
- 13:43SPEAKER_01: or a significant aviation disruption that grounds their network.
- 13:46SPEAKER_00: Here's where it gets really interesting.
- 13:49SPEAKER_00: Because medical usefulness
- 13:50SPEAKER_00: and essential patient demand do not automatically guarantee shareholder returns.
- 13:54SPEAKER_00: No, they don't.
- 13:55SPEAKER_00: Hospital budgets still exist.
- 13:57SPEAKER_00: Donor supply is still naturally limited.
- 14:00SPEAKER_00: Competitors are still out there trying to solve the same problems.
- 14:03SPEAKER_00: There are no guaranteed monopolies here just because the technology is life-saving.
- 14:07SPEAKER_01: No, they don't.
- 14:07SPEAKER_01: Which perfectly frames the alpha gap, the central debate happening among investors right now.
- 14:13SPEAKER_00: Yeah.
- 14:14SPEAKER_01: Are the skeptics mistaking necessary heavy investment spending
- 14:19SPEAKER_01: for a permanent deterioration of the business model?
- 14:23SPEAKER_01: Or on the flip side, are the enthusiasts mistaking
- 14:26SPEAKER_01: a highly useful logistical network for an endlessly high margin business?
- 14:31SPEAKER_00: Right, because flying more organs might lower the unit cost per trip,
- 14:34SPEAKER_00: but buying and maintaining planes and keeping specialist teams
- 14:37SPEAKER_00: on call never becomes costless.
- 14:40SPEAKER_01: Exactly. And future SEC filings on margins and operating cash conversion are
- 14:45SPEAKER_01: the only tangible evidence that will settle that debate.
- 14:48SPEAKER_01: When we look at the substantive advisor disagreement,
- 14:51SPEAKER_01: the research we are referencing includes exactly 14 research contributions
- 14:56SPEAKER_01: across exactly three model families.
- 14:59SPEAKER_00: And we need to explain what that actually means.
- 15:01SPEAKER_00: 14 research contributions, three model families.
- 15:04SPEAKER_00: These are correlated AI perspectives.
- 15:07SPEAKER_00: They are not 14 independent human analysts sitting in a room voting on the stock.
- 15:11SPEAKER_01: Correct. And the core debate between these models is stark.
- 15:15SPEAKER_01: You have a cautious case that is targeting valuations in the mid 140s by 2031.
- 15:20SPEAKER_00: Okay.
- 15:21SPEAKER_01: That cautious model requires the earnings to do all the heavy lifting
- 15:24SPEAKER_01: without relying on the market magically granting them a higher valuation multiple.
- 15:29SPEAKER_00: In the optimistic case?
- 15:30SPEAKER_01: Then you have a much more optimistic network thesis.
- 15:34SPEAKER_01: That contribution sees revenue eventually hitting roughly one
- 15:37SPEAKER_01: and two-thirds billion dollars, operating margins expanding to around 26 percent,
- 15:43SPEAKER_01: and valuations soaring above $200.
- 15:46SPEAKER_00: So the true disagreement isn't about whether the worm perfusion technology works clinically.
- 15:50SPEAKER_00: That's proven.
- 15:51SPEAKER_01: Right.
- 15:52SPEAKER_00: It is entirely about what profit margin this hybrid device
- 15:56SPEAKER_00: and aviation business can actually earn when it reaches full scale.
- 16:00SPEAKER_00: So what milestones should we be watching for next to see which model is right?
- 16:04SPEAKER_01: In the short term, you need to watch case growth, organic revenue,
- 16:08SPEAKER_01: service profitability, and crucially that cash conversion metric.
- 16:13SPEAKER_00: Got it. What about the timeline?
- 16:15SPEAKER_01: Timeline-wise, early 2027 is all about digesting these massive research
- 16:20SPEAKER_01: and infrastructure costs.
- 16:22SPEAKER_01: By late 2027, the market will demand visible progress on those margins.
- 16:26SPEAKER_00: And 2028?
- 16:28SPEAKER_01: 2028 is the major hurdle, because that is when the maturity
- 16:31SPEAKER_01: of those $460 million convertible notes arrives.
- 16:35SPEAKER_00: You mentioned kidneys earlier as the massive upsar tail.
- 16:38SPEAKER_00: What is the actual timeline there?
- 16:41SPEAKER_01: The company expects its first human experience with OCS kidney in the second half of 2027.
- 16:47SPEAKER_00: Let's underline that phrasing carefully.
- 16:49SPEAKER_00: First human experience means the very beginning of clinical evidence.
- 16:52SPEAKER_00: It is absolutely not an approved commercial launch.
- 16:55SPEAKER_00: We are a long, long way from unrestricted sales.
- 16:58SPEAKER_01: Very true.
- 16:59SPEAKER_01: Now, to understand where the business is currently heading,
- 17:02SPEAKER_01: we have to track the recent changes in their data very carefully.
- 17:05SPEAKER_00: Okay.
- 17:06SPEAKER_01: If we compare the July research to today,
- 17:08SPEAKER_01: we first saw the completion of the pad aviation investment in July.
- 17:12SPEAKER_01: Then in August, their second quarter results showed revenue of roughly $190 million,
- 17:17SPEAKER_01: which was up about 21%, alongside sharply higher research spending.
- 17:22SPEAKER_00: That was really the moment where the pivot from purely selling medical devices
- 17:26SPEAKER_00: to becoming a massive clinical
- 17:28SPEAKER_00: and logistics infrastructure player became totally concrete for the market.
- 17:32SPEAKER_01: Yes, it stopped being a theory and became reality.
- 17:35SPEAKER_01: And then the November updates added even more critical data.
- 17:38SPEAKER_01: We saw that third quarter organic growth of 35%.
- 17:42SPEAKER_01: We saw they won an Italian logistics tender.
- 17:45SPEAKER_01: And in October, they received FDA investigational exemptions
- 17:48SPEAKER_01: for enhanced heart part B and de novo lung.
- 17:51SPEAKER_00: And again, we need to translate those exemptions.
- 17:54SPEAKER_00: An investigational exemption permits clinical studies to occur.
- 17:58SPEAKER_00: And in these specific studies, the company's cold preservation system acts as the control arm.
- 18:03SPEAKER_00: Exactly.
- 18:04SPEAKER_00: These exemptions do not equal unrestricted commercial approval from the FDA.
- 18:08SPEAKER_00: We have to keep our expectations grounded in the clinical reality.
- 18:12SPEAKER_00: What about their forward looking revenue guidance?
- 18:14SPEAKER_01: Their full year revenue guidance explicitly excluding PAD is about 750 to 760 million dollars.
- 18:22SPEAKER_00: And let's explain why they are excluding PAD from that specific guidance metric
- 18:26SPEAKER_00: because it confuses a lot of people.
- 18:29SPEAKER_00: It is strictly for organic comparability.
- 18:32SPEAKER_00: It is not because of FAA rules and it is not because of minority ownership issues.
- 18:37SPEAKER_00: PAD is a European aviation investment.
- 18:40SPEAKER_00: Under accounting rules, it is consolidated as a variable interest entity.
- 18:44SPEAKER_01: Meaning what exactly for the casual listener?
- 18:46SPEAKER_00: Basically, that means even though transmedics might not own 100% of it,
- 18:50SPEAKER_00: they have enough economic control that the rules force them to put it
- 18:53SPEAKER_00: on their balance sheet.
- 18:54SPEAKER_01: Oh, I see.
- 18:55SPEAKER_00: But when management talks to Wall Street,
- 18:57SPEAKER_00: they strip it out of the guidance so investors can see the pure organic growth
- 19:01SPEAKER_00: of the core business.
- 19:03SPEAKER_00: So we have to keep the legal accounting reality entirely separate
- 19:06SPEAKER_00: from the organic guidance numbers.
- 19:08SPEAKER_01: Exactly.
- 19:08SPEAKER_01: It is all about comparing apples to apples for their core operational growth.
- 19:13SPEAKER_01: You know, thinking about these highly unique financial and funding structures,
- 19:18SPEAKER_01: it naturally brings to mind our last public stock deep dive on Eden Red, episode 42.
- 19:24SPEAKER_00: Oh, that's a brilliant comparison, but also a really important contrast.
- 19:28SPEAKER_01: How so?
- 19:29SPEAKER_00: Well, Eden Red's massive payment network
- 19:31SPEAKER_00: and how they handle client prepaid balances pose completely different funding
- 19:35SPEAKER_00: questions compared to Transmedics.
- 19:37SPEAKER_00: Transmedics is dealing with heavy physical infrastructure like airplanes
- 19:41SPEAKER_00: and facilities alongside clinical trials and massive working capital needs.
- 19:45SPEAKER_00: They are very different beasts when it comes to cash flow.
- 19:47SPEAKER_01: They absolutely are.
- 19:50SPEAKER_01: So considering all of this infrastructure weight,
- 19:52SPEAKER_01: what would invalidate the optimistic thesis for Transmedics?
- 19:55SPEAKER_01: Like what breaks the bull case?
- 19:58SPEAKER_00: I mean, if their case revenue keeps growing at 35 percent,
- 20:01SPEAKER_00: but it repeatedly fails to actually improve their cash conversion,
- 20:05SPEAKER_00: or if their service margins continue to worsen as the aviation network gets bigger
- 20:10SPEAKER_00: and more complex.
- 20:11SPEAKER_01: Yeah, that would be bad.
- 20:13SPEAKER_00: Or perhaps most dangerously,
- 20:14SPEAKER_00: if their property and development commitments demand way more outside financing
- 20:18SPEAKER_00: than anyone expects right now, heavily diluting the current shareholders.
- 20:22SPEAKER_01: Conversely, if they show sustained organic demand from surgeons paired
- 20:27SPEAKER_01: with actually improving service economics
- 20:30SPEAKER_01: and healthy free cash generation post-investment,
- 20:33SPEAKER_01: that would heavily strengthen the optimistic case and prove
- 20:36SPEAKER_01: the infrastructure spend was worth it.
- 20:38SPEAKER_00: So what does this all mean?
- 20:40SPEAKER_01: It means Transmedics has the very real potential to become a massive,
- 20:45SPEAKER_01: indispensable infrastructure platform for the entire organ transplant industry.
- 20:49SPEAKER_01: But achieving medical progress, driving top-line revenue growth,
- 20:53SPEAKER_01: and actually delivering compounding shareholder returns are three entirely separate
- 20:58SPEAKER_01: achievements. That longer-term strong buy rating depends entirely
- 21:03SPEAKER_01: on relentless operational execution and incredibly strict funding discipline.
- 21:08SPEAKER_00: For the bigger picture, visit iPulse AI to explore our complete rankings
- 21:11SPEAKER_00: of covered assets, discover the strongest buys,
- 21:14SPEAKER_00: and see the research behind the ratings all in one place.
- 21:17SPEAKER_01: Primary research conducted through the iPulse AI platform by Future Edge Group.
- 21:22SPEAKER_01: Please like, comment, and subscribe.
- 21:25SPEAKER_01: We are publishing a new podcast every Monday through Friday.
- 21:28SPEAKER_01: Stay tuned for the next podcast on Booking Holdings.
- 21:31SPEAKER_00: And speaking of Booking.com,
- 21:33SPEAKER_00: it is fascinating to think about how they connect massive global travel demand using
- 21:37SPEAKER_00: a completely different digital platform and an entirely different cash flow model
- 21:42SPEAKER_00: than the heavy physical aviation infrastructure we just explored today.
- 21:46SPEAKER_00: Something to think about until next time.